Migraine With Aura | Efficacy of Sumatriptan With Naprosyn in Migraine With Aura
Migraine With Aura research study
What is the primary objective of this study?
This is a double-blinded placebo study, examining the efficacy of Sumatriptan with Naprosyn in the treatment of migraine with aura.
Who is eligible to participate?
Inclusion Criteria: - Subjects must be 18 to 50 years of age, inclusive. - Patients will meet the International Headache Society (IHS) classification criteria for migraine with aura. - Subjects must carry the diagnosis of 1-2 migraine with aura per month for at least three months before study inclusion. and migraine with aura were included in the study - Subjects must have an onset of a visual aura that occurs 15-30 minutes before a migraine headache. - Subjects must be able to understand and complete a migraine diary. - Subjects must be able to distinguish a migraine with aura from other types of headache. - Subjects must be in generally good health as confirmed by medical and medication history, baseline physical and neurological exam and vital signs. - Female subjects must be either a) postmenopausal for one year, b)surgically sterile, c) practicing acceptable birth control for at least one month prior to screening and throughout study, or d) practicing abstinence and agree to continue same throughout study. Exclusion Criteria: - Subjects who have a significant systemic disease other than migraine that is equally painful or more painful. - Subjects who have other progressive neurological disorders. - Subjects who have more than 8 migraines or 15 headache days per month. - Subjects who have previously taken Treximet and failed due to lack of efficacy or adverse side effects. - Subjects who carry the diagnosis of chronic tension type headache or cluster headache based on the International Headache Society criteria. - Subject should not have received any other investigative drug within 3 months prior to enrollment in the study. - Subject who have the diagnosis of seizure disorder, chronic daily headache, uncontrolled hypertension, cardiovascular disease, history of stroke, basilar or hemiplegic migraine, hepatic disease, or active peptic ulcer disease. - Subjects currently taking or in 3 months prior to study, use of prophylactic migraine medications. - Subjects who have a known allergy to Sumatriptan or Naprosyn. - Subjects who in the opinion of Dr. Mechtler have a condition for which they should not be enrolled in the study.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Migraine With Aura
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:sumatriptan with naprosynSubjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
Drug:placeboSubjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
1Placebo taken at onset of aura associated with migraine.
2Sumatriptan with naprosyn taken at onset of aura associated with migraine.
Start Date: October 2010
Completed Date: December 2015
Primary Outcome: Primary outcome measure will be comparative percentage of patients pain free at 2 and 4 hours from initiating treatment with placebo vs treatment with Treximet (sumatriptan with naprosyn).
Secondary Outcome: Secondary outcomes will be percentage of patients with pain relief at 2 and 4 hours.
Study sponsors, principal investigator, and references
Principal Investigator: Laszlo L Mechtler, MD
Lead Sponsor: Dent Neurologic Institute